Vlasic Labs CBD Products Qualify for CMS Medicare Pilot Program

BLOOMFIELD HILLS – Vlasic Labs announced that its cannabidiol product line meets the qualification standards for a new federal pilot program run by the Centers for Medicare and Medicaid Services.

The Michigan company’s hemp-derived offerings now satisfy the requirements of the Substance Access Beneficiary Engagement Incentive, a limited initiative that lets certain participating healthcare organizations supply eligible hemp products directly to Medicare beneficiaries. Under the program, providers in three specific CMS Innovation Center models can furnish up to $500 worth of qualifying products per eligible beneficiary each year to help manage symptoms.

The pilot, which begins April 1 for the ACO REACH and Enhancing Oncology models and January 2027 for the Long-term Enhanced ACO Design (LEAD) model, operates through accountable care organizations and other selected participants. Organizations must submit detailed implementation plans, and products must be provided by affiliated physicians after documented consultations on benefits, risks, and potential drug interactions. Medicare itself does not reimburse claims for the products; providers handle procurement and distribution.

To qualify, hemp products must be orally administered, contain no more than 0.3% delta-9 THC on a dry-weight basis, and deliver no more than 3 milligrams of total THC per serving. They cannot include synthetic cannabinoids or inhalable forms and must pass third-party testing for potency, contaminants and safety while complying with federal, state and local laws.

Vlasic Labs, known for its line of tinctures, topicals and other wellness items, stated that its formulations align with these criteria. In a company statement, CEO Willy Vlasic noted the firm’s focus on consistent, tested products and expressed readiness to support participating providers as the program rolls out.

The development arrives just weeks after CMS published detailed guidance on the incentive and as the broader hemp sector adjusts to recent federal rules on cannabinoid content and testing. A handful of other manufacturers have welcomed the guidance, but Vlasic Labs is among the first to publicly confirm product-line eligibility.

For now, the pilot remains narrow in scope. Only beneficiaries aligned with electing organizations qualify, and participation requires strict oversight to prevent inducement or program abuse. CMS has emphasized that the effort will generate data on real-world use while collecting quarterly reports from participants.

The announcement highlights how a small group of compliant hemp producers could gain early footholds in federal healthcare channels. It also illustrates the cautious pace at which regulators are testing cannabinoid integration for older adults, the primary Medicare population. Outcomes from this initial phase could influence whether similar incentives expand or remain confined to innovation models.